Olgu Sunumu
Yıl 2021,
Cilt: 43 Sayı: 1, 97 - 99, 31.03.2021
Öz
Kaynakça
- 1- Gedikli, M. A., Tuzun, B., Aktas, A., Sayin, K., & Ataseven, H. (2021). Areclarithromycin, azithromycinandtheiranalogueseffective in thetreatment of COVID19?. Bratislavskelekarskelisty, 122(2), 101-110.
- 2- Aktas, A., Tuzun, B., Taskin, A. H., Sayin, K. O. R. A. Y., & Ataseven, H. (2020). How do arbidolanditsanalogsinhibitthe SARS-CoV-2?. Bratislavskelekarskelisty, 121(10), 705-711.
- 3- Aktaş, A.,Sener, K., Yılmaz, N., Tunç, M., & Yolcu, S. (2020). Is MeanPlatelet Volume UsefulforPredictingthePrognosis of COVID-19 DiagnosedPatients?. Age, 54(18,191), 18-191.
- 4- Huzmeli, C., Candan, F., Bagci, G., Alaygut, D., Yilmaz, A., Gedikli, A., ... &Kayatas, M. (2017). Frequency of familialMediterraneanfever (MEFV) gene mutations in patientswithbiopsy-provenprimaryglomerulonephritis. Clinicalrheumatology, 36(11), 2589-2594.
- 5- Becker, R. C. (2020). COVID-19-associated vasculitisandvasculopathy.
- 6- Iba, T.,Connors, J. M., &Levy, J. H. (2020). Thecoagulopathy, endotheliopathy, andvasculitis of COVID-19. InflammationResearch, 1-9.
Yıl 2021,
Cilt: 43 Sayı: 1, 97 - 99, 31.03.2021
Öz
This disease, which is called COVID-19 disease due to the SARS COV2 virus, which emerged as a result of the mutation of the coronavirus in China in 2019, and caused significant morbidity and mortality all over the world due to the pandemic it created, has become the world's most important health problem. COVID-19 clinic emerges in a wide spectrum from mild viral infection to severe respiratory failure. COVID-19 is thought to be a syndrome that involves multiple organs and systems in various ways, especially endothelial damage.With this case, we wanted to emphasize that this virus is not only isolated in the respiratory system and should be kept in mind in today's conditions among the rare causes of vasculitis.
Anahtar Kelimeler
Kaynakça
- 1- Gedikli, M. A., Tuzun, B., Aktas, A., Sayin, K., & Ataseven, H. (2021). Areclarithromycin, azithromycinandtheiranalogueseffective in thetreatment of COVID19?. Bratislavskelekarskelisty, 122(2), 101-110.
- 2- Aktas, A., Tuzun, B., Taskin, A. H., Sayin, K. O. R. A. Y., & Ataseven, H. (2020). How do arbidolanditsanalogsinhibitthe SARS-CoV-2?. Bratislavskelekarskelisty, 121(10), 705-711.
- 3- Aktaş, A.,Sener, K., Yılmaz, N., Tunç, M., & Yolcu, S. (2020). Is MeanPlatelet Volume UsefulforPredictingthePrognosis of COVID-19 DiagnosedPatients?. Age, 54(18,191), 18-191.
- 4- Huzmeli, C., Candan, F., Bagci, G., Alaygut, D., Yilmaz, A., Gedikli, A., ... &Kayatas, M. (2017). Frequency of familialMediterraneanfever (MEFV) gene mutations in patientswithbiopsy-provenprimaryglomerulonephritis. Clinicalrheumatology, 36(11), 2589-2594.
- 5- Becker, R. C. (2020). COVID-19-associated vasculitisandvasculopathy.
- 6- Iba, T.,Connors, J. M., &Levy, J. H. (2020). Thecoagulopathy, endotheliopathy, andvasculitis of COVID-19. InflammationResearch, 1-9.
Toplam 6 adet kaynakça vardır.
Ayrıntılar
| Birincil Dil | İngilizce |
|---|---|
| Konular | Sağlık Kurumları Yönetimi |
| Bölüm | Olgu Sunumu |
| Yazarlar | |
| Kabul Tarihi | 26 Mart 2021 |
| Yayımlanma Tarihi | 31 Mart 2021 |
| DOI | https://doi.org/10.7197/cmj.890173 |
| IZ | https://izlik.org/JA79UL64LF |
| Yayımlandığı Sayı | Yıl 2021 Cilt: 43 Sayı: 1 |